Medpace (NASDAQ:MEDP) Stock Price Down 0.1%

Shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Get Free Report) dropped 0.1% during mid-day trading on Friday . The company traded as low as $388.88 and last traded at $389.46. Approximately 28,702 shares changed hands during mid-day trading, a decline of 88% from the average daily volume of 249,331 shares. The stock had previously closed at $389.77.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the stock. UBS Group upgraded shares of Medpace from a "neutral" rating to a "buy" rating and lifted their target price for the company from $282.00 to $452.00 in a research note on Thursday, February 15th. Deutsche Bank Aktiengesellschaft started coverage on Medpace in a research report on Monday, March 18th. They issued a "hold" rating and a $395.00 price objective on the stock. Robert W. Baird boosted their price target on Medpace from $446.00 to $454.00 and gave the stock an "outperform" rating in a report on Wednesday. Guggenheim increased their price objective on shares of Medpace from $453.00 to $464.00 and gave the company a "buy" rating in a report on Wednesday. Finally, StockNews.com raised shares of Medpace from a "hold" rating to a "buy" rating in a report on Tuesday. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, Medpace has an average rating of "Moderate Buy" and a consensus price target of $443.00.

Medpace Stock Performance

The firm's fifty day simple moving average is $397.75 and its 200 day simple moving average is $324.12. The firm has a market cap of $12.27 billion, a P/E ratio of 39.70, a P/E/G ratio of 1.98 and a beta of 1.38.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its quarterly earnings results on Monday, April 22nd. The company reported $3.20 EPS for the quarter, beating analysts' consensus estimates of $2.45 by $0.75. Medpace had a net margin of 15.92% and a return on equity of 59.74%. The firm had revenue of $511.00 million during the quarter, compared to the consensus estimate of $512.39 million. During the same quarter last year, the firm earned $2.27 EPS. The firm's revenue for the quarter was up 17.7% compared to the same quarter last year. On average, equities research analysts predict that Medpace Holdings, Inc. will post 11.23 earnings per share for the current year.

Insider Activity at Medpace

In related news, major shareholder Medpace Investors, Llc sold 50,000 shares of the stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $391.75, for a total value of $19,587,500.00. Following the completion of the transaction, the insider now owns 5,539,947 shares of the company's stock, valued at approximately $2,170,274,237.25. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, VP Susan E. Burwig sold 102 shares of the stock in a transaction dated Friday, March 15th. The shares were sold at an average price of $403.00, for a total value of $41,106.00. Following the sale, the vice president now directly owns 15,181 shares of the company's stock, valued at approximately $6,117,943. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Medpace Investors, Llc sold 50,000 shares of the stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $391.75, for a total transaction of $19,587,500.00. Following the completion of the sale, the insider now directly owns 5,539,947 shares in the company, valued at $2,170,274,237.25. The disclosure for this sale can be found here. In the last quarter, insiders sold 189,340 shares of company stock valued at $76,651,647. Insiders own 20.30% of the company's stock.

Institutional Trading of Medpace

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. RiverPark Advisors LLC purchased a new stake in Medpace in the 4th quarter worth about $26,000. Contravisory Investment Management Inc. purchased a new position in shares of Medpace during the fourth quarter worth approximately $26,000. Rise Advisors LLC purchased a new position in shares of Medpace during the first quarter worth approximately $27,000. Mather Group LLC. purchased a new position in shares of Medpace during the first quarter worth approximately $28,000. Finally, FinTrust Capital Advisors LLC purchased a new position in shares of Medpace during the third quarter worth approximately $30,000. 77.98% of the stock is owned by hedge funds and other institutional investors.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.